Bentley Pharma to use Cardinal's facility for nasal insulin manufacture

By Emilie Reymond

- Last updated on GMT

Related tags Pharmacology Cardinal

Bentley Pharmaceuticals has announced it will use the North
Carolina facilities of US-based services provider Cardinal Health
for the scale-up and manufacture of the clinical supplies of its
new intranasal insulin product.

The US firm plans to use Cardinal's facility to help it have enough of the trial drug ready in order to expand its global Phase II clinical trials program by the end of the year, but stressed that it is still "in charge of the manufacturing process".

The two companies are already in partnership for the development of the drug with Bentley using Cardinal's other analytical services facility, also based in North Carolina.

"By using Cardinal's full range of solutions, from development to manufacturing and distribution, Bentley maximizes its efficiency and relies on the same high-quality services through the entire drug development and commercialisation cycle,"​ said Cardinal's vice president Shawn Gallagher.

The product candidate uses Bentley's proprietary drug delivery technology, called CPE-215, to deliver insulin directly through diabetic patients' nasal mucosa using a nasal spray.

Currently used treatments require intramuscular injections several times a day.

"There is growing interest in alternative insulin delivery methods that are less intrusive than injection,"​ said John Sedor, Bentley's president.

Bentley recently signed a license agreement with Korea's Dong Sung and India's Biocon to develop and market the product in 85 countries throughout Asia, Africa, and the Middle East upon approval.

Related news

Show more

Related products

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 04-May-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Content provided by Lonza Small Molecules | 28-Mar-2023 | White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Related suppliers

Follow us

Products

View more

Webinars